Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Open Badges Poster presentation

Broad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamas

LE McCoy1*, L Rutten2, G Dekkers1, C Blanchetot3, NM Strokappe4, A Forsman-Quigley1, MS Seaman5, H de Haard3, T Verrips4 and RA Weiss1

  • * Corresponding author: LE McCoy

Author Affiliations

1 University College London, London, UK

2 Biomolecular Imaging, Department Biology, University of Utrecht, Utrecht, the Netherlands

3 arGEN-X BVBA, Ghent, Belgium

4 Biomolecular Imaging, Department Biology, Utrecht University, Utrecht, the Netherlands

5 Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA, USA

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P94  doi:10.1186/1742-4690-9-S2-P94

The electronic version of this article is the complete one and can be found online at:

Published:13 September 2012

© 2012 McCoy et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Llamas naturally produce heavy chain only antibodies in addition to conventional antibodies. The variable regions of the heavy chain (VHH) demonstrate comparable affinity and specificity for antigens with conventional immunoglobulins. To date, immunizations in human and animal models have yielded only antibodies with limited ability to neutralize human immunodeficiency virus (HIV)-1.


A VHH (J3) isolated from a llama multiply-immunized with recombinant trimeric HIV-1 envelope proteins (Env) was found to neutralize 96 of 100 HIV-1 strains, encompassing subtypes A, B, C, D, BC, AE, AG, AC, ACD, CD and G. Isolation involved expression of VHH in E. coli and analysis of neutralization ability in TZM-bl reporter cells.


Newly isolated VHH from multiple immunized llamas also have broad and potent HIV-1 neutralization activity. J3 targets HIV-1 via the CD4-binding site and neutralization is seen when J3 is used in combination with VHH targeting other Env epitopes. VHH-human FC fusion heavy-chain only antibodies (VHH-FC) have been constructed and J3 activity is not only preserved in this context but enhanced.


This study shows that experimental immunization with recombinant HIV-1 Env can elicit broad neutralizing heavy-chain only antibodies and supports the development of VHH and VHH-FC as anti-HIV-1 microbicides and therapeutics.